Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Kodiak SciencesMEX:KOD 27 Debt-to-Equity is 0.50 as of Mar. 2026, which is 213% above its 10-year median of 0.16. GuruFocus rates MEX:KOD with a GF Score™ of 27/100. The stock has 4 warning signs investors should review. Among 967 Biotechnology companies, Kodiak Sciences ranks worse than 75.59% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Kodiak Sciences's Debt-to-Equity or its related term are showing as below:
MEX:KOD'
s Debt-to-Equity Range Over the Past 10 Years
Min: -0.44 Med: 0.16 Max: 2.63
Current: 0.5
During the past 10 years, the highest Debt-to-Equity Ratio of Kodiak Sciences was 2.63. The lowest was -0.44. And the median was 0.16.
MEX:KOD's Debt-to-Equity is ranked worse than 75.59% of 967
companies
in the Biotechnology industry
Industry Median: 0.16
vs MEX:KOD: 0.50
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Kodiak Sciences Debt-to-Equity Related Terms
Kodiak Sciences Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Kodiak Sciences's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:KOD vs BEAM, TARS, VERA: Debt-to-Equity Comparison
For the Biotechnology subindustry, Kodiak Sciences's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kodiak Sciences Debt-to-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Kodiak Sciences's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Kodiak Sciences's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kodiak Sciences (MEX:KOD) has a Debt-to-Equity of 0.50 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Kodiak Sciences and its competitors. This is 213% above median its historical median of 0.16. According to the industry distribution chart, Kodiak Sciences ranks #731 out of 967 companies in the Biotechnology industry, placing it in the top 75.6%.
Is Kodiak Sciences' Debt-to-Equity too high?
Kodiak Sciences' current Debt-to-Equity of 0.50 is 213% above median its 10-year median of 0.16. The Biotechnology industry median Debt-to-Equity is 0.16. Kodiak Sciences' value of 0.50 is 212.5% above this industry median. Based on the distribution chart, Kodiak Sciences ranks #731 out of 967 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Kodiak Sciences has a GF Score™ of 27/100, reflecting its overall financial health beyond just this single metric.
How does Kodiak Sciences' Debt-to-Equity compare to BEAM and TARS?
According to the Biotechnology industry distribution chart, Kodiak Sciences ranks #731 out of 967 companies for Debt-to-Equity. This places Kodiak Sciences in the lower half of its industry. The industry median Debt-to-Equity is 0.16. Kodiak Sciences' value of 0.50 is 212.5% above this benchmark. While the company's 10-year median is 0.16 vs. the industry median of 0.16, Kodiak Sciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.16, based on 967 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Kodiak Sciences's current Debt-to-Equity of 0.50 is 212.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Kodiak Sciences and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kodiak Sciences's current Debt-to-Equity is 0.50, which is 213% above median its own 10-year median of 0.16. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kodiak Sciences stock overvalued right now?
Kodiak Sciences (MEX:KOD) has a current Debt-to-Equity of 0.50. The current Debt-to-Equity is 0.50, which is 213% above median its 10-year median of 0.16 and 212.5% above the Biotechnology industry median of 0.16. Kodiak Sciences' overall GF Score™ is 27/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Kodiak Sciences (MEX:KOD), the current Debt-to-Equity is 0.50 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Kodiak Sciences Inc has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) platform, for retinal medicines. Its investigational medicine, tarcocimab tedromer (Zenkuda or tarcocimab), is an anti-VEGF therapy built on Kodiak's proprietary ABC platform. Another investigational medicine, KSI-501, is an anti-interleukin 6, or IL-6, VEGF-trap bispecific therapy built on the ABC platform and is being developed for high-prevalence retinal vascular diseases and intended to address the unmet needs of extended durability and targeting disease biology beyond VEGF for differentiated efficacy. Its third investigational medicine, KSI-101, is a high-strength (100 mg/mL) bispecific protein targeting IL-6 and VEGF.
27GF Score
Get the complete analysis for MEX:KOD
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:KOD has been successfully added to your 
